|
2010-12-27 |
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. |
CIM |
Registered |
|
2010-12-27 |
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. |
CIM |
Registered |
|
2010-12-27 |
Hebervis administration in patients suffering from buccal mucositis caused by chemotherapy [unsealed |
CIGB |
Registered |
|
2010-12-28 |
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients |
CIM |
Registered |
|
2010-12-28 |
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients |
CIM |
Registered |
|
2010-12-28 |
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. |
CIM |
Registered |
|
2010-12-28 |
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. |
CIM |
Registered |
|
2010-12-28 |
InCarbacel-II |
CIGB |
Registered |
|
2010-12-29 |
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. |
CIM |
Registered |
|
2010-12-29 |
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. |
CIM |
Registered |
|
2010-12-29 |
Patients with non small cells lung cancer (NSCLC) and brain metastasis. |
CIM |
Registered |
|
2010-12-29 |
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. |
CIM |
Registered |
|
2010-12-29 |
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. |
CIM |
Registered |
|
2010-12-29 |
14F7 MAb marked with Tc99 Phase II in breast tumors. |
CIM |
Registered |
|
2011-04-18 |
Early use of surfacen in the respiratory distress syndrome of the newborn. Phase IV |
CENSA |
Registered |
|
2011-04-27 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks. |
CIGB |
Registered |
|
2011-04-28 |
Alum Phospate Adjuvated QuimiHib® Vaccine Clinical Study. |
CIGB |
Registered |
|
2011-04-29 |
CENTAURO Study |
CIGB |
Registered |
|
2011-04-29 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months. |
CIGB |
Registered |
|
2011-04-30 |
NEUVITAL V Study |
CIGB |
Registered |
